Efficacy of different AV7909 dose regimens in a nonclinical model of pulmonary anthrax

Efficacy of different AV7909 dose regimens in a nonclinical model of pulmonary anthrax

ABSTRACTPulmonary anthrax caused by exposure to inhaled Bacillus anthracis, the most lethal form of anthrax disease, is a continued military and public health concern for the United States. The vaccine AV7909, consisting of the licensed anthrax drug substance AVA adjuvanted with CpG7909, induces hig...

Full description

Bibliographic Details
Main Authors: Lisa Henning, Michael Anderson, Cheryl Triplett, Tammy Smith, Kevin Boyce, Lindsay Hendey, Alex Ridenour, Jason Eng, David Schaeufele, Ehran Wilson, Carol L. Sabourin, Lily E. Adams, Tahar Babas, Lindsay Parish, Daniel Wolfe
Format: Article
Language:English
Published: Taylor & Francis Group 2023-12-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
Anthrax
vaccine
Bacillus anthracis
BARDA
post-exposure prophylaxis
Online Access:https://www.tandfonline.com/doi/10.1080/21645515.2023.2290345

Internet

https://www.tandfonline.com/doi/10.1080/21645515.2023.2290345

Similar Items